bioRxivCell BiologyPreprint
Active Enterohepatic Cycling is Not Required for the Choleretic Actions of 24-norUrsodeoxycholic Acid in Mice
J. Li, J. K. Truong, K. Pachura, A. Rao, S. Gambeer, C. D. Fuchs, S. J. Karpen, M. J. Trauner, P. A. Dawson
Abstract
The superior ability of norursodeoxycholic acid (norUDCA) to induce a bicarbonate-rich hypercholeresis has been attributed to its ability to undergo cholehepatic shunting and norUDCA is currently being evaluated as a therapeutic for forms of liver disease. The goal of this study was to use mouse models to investigate contributions of bile acid transporters to the choleretic actions of norUDCA. Here, we show that the apical sodium-dependent bile acid transporter (ASBT) and Organic solute transporter-alpha (OST) are dispensable for norUDCA-stimulation of bile flow and biliary bicarbonate secretion in mice. Analysis of the liver transcriptome revealed that norUDCA induced hepatic expression of a limited number of transporter genes, particularly organic anion transporting polypeptide 1a4 (Oatp1a4). However, norUDCA potently stimulated a bicarbonate-rich hypercholeresis in Oatp1a/1b-deficient mice. Blocking intestinal bile acid reabsorption by co-administration of an ASBT inhibitor or bile acid sequestrant did not impact the ability of norUDCA to induce bile flow in wildtype mice. The results support the concept that these major bile acid transporters are not directly involved in the absorption, cholehepatic shunting, or choleretic actions of norUDCA. Additionally, the findings support further investigation of the therapeutic synergy between norUDCA and ASBT inhibitors or bile acid sequestrants for cholestatic liver disease.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mineralocorticoid receptor-independent activation of ENaC in bile duct ligated mice
X.-P. Wang, S. M. Mutchler, … O. B. Kashlan·Journal of the American Society of NephrologyPeer-reviewed·Jul 10, 2024
- Selective Agonism of Liver and Gut FXR Prevents Cholestasis and Intestinal Atrophy in Parenterally Fed Neonatal Pigs
Yanjun Jiang, Zhengfeng Fang, … Douglas G. Burrin·Journal of Lipid ResearchPeer-reviewed·Oct 1, 2025
- Secondary bile acid ursodeoxycholic acid (UDCA) alters weight, the gut microbiota, and the bile acid pool in conventional mice
J. A. Winston, A. Rivera, … C. M. Theriot·bioRxiv·Jul 11, 2019
- GLUCURONIDATION: THE LAST DEFENSIVE LINE AGAINST BILEACID TOXICITY DURING CHOLESTASIS.
Jocelyn Trottiet, Audrey-Anne Lavoie, … Olivier Barbier·bioRxiv·Aug 23, 2025
- Uttroside B, a US-FDA-Designated Orphan Drug Against Hepatocellular Carcinoma (HCC), Impedes Non-alcoholic Steatohepatitis (NASH) and NASH -Induced HCC
Tennyson Prakash Rayginia, Chenicheri Kizhakkeveettil Keerthana, … Ruby John Anto·bioRxiv·Nov 6, 2024
- Molecular Mechanisms of Na+-driven Bile Acid Transport in Human NTCP